ReviewFrontiers in oncology2025
Research advances in the adjunctive diagnosis of acute myeloid leukemia.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Artificial Intelligence for Personalized Management of Acute Myeloid Leukemia.Journal of personalized medicine · 2026Review
- Immune monitoring for relapse of acute myeloid leukemia after allogeneic stem cell transplantation in clinical laboratories.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute myeloid leukemia (AML) is a highly heterogeneous malignant hematological neoplasm. Although standard diagnostic procedures have been established, traditional methods still face limitations with regard to efficiency, accuracy, and standardization. In recent years, artificial intelligence (AI) has demonstrated notable advantages in medical image analysis, flow cytometry interpretation, and genetic data modeling, offering new approaches for adjunctive diagnosis of AML. This review systematically summarizes recent research advances in adjunctive diagnosis of AML, categorizing current AI-based approaches based on data modality into three groups: blood smear image analysis, flow cytometry data interpretation, and genetic data modeling. We focus on the application strategies, diagnostic performance, and limitations of these approaches. Studies have shown that AI not only enhances diagnostic efficiency and reduces subjective bias, but also holds promise in identifying novel biomarkers. Nevertheless, current models still suffer from limited generalizability and insufficient clinical interpretability. Future efforts should prioritize data standardization, improve model transparency, and facilitate the seamless integration of AI systems into clinical workflows to support precision diagnosis and treatment of AML.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.